IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $IMV #DeliveryPlatform–IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it plans to maintain its existing at-the-market facility initially announced on October 16, 2020 under its recently renewed base shelf prospectus, which is effective for a period of 25 months from July 25, 2
Click here to view original post